We have top scientific researchers, oncologists, and the most professional service team.
Since our establishment, we have been committed to providing professional services to oncology researchers around the world.
Our team works closely together and is passionate about completing every task assigned by our customers.
Alfa Cytology is committed to providing customers with comprehensive support in the fields of biological, chemical and pharmaceutical research. Our team, comprised of seasoned professionals, collaborates with researchers to efficiently conduct breast cancer studies, exploring innovative approaches for both diagnosis and treatment.
We offer specialized services to address the unique needs of different breast cancer types, ensuring targeted and effective treatments.
We develop various molecular therapies to offer innovative breast cancer treatments.
Comprehensive services for developing small molecule drugs that offer targeted and efficient treatment options for breast cancer.
Cutting-edge solutions for creating therapeutic antibodies that specifically target breast cancer cells.
Advanced gene therapy development services aimed at altering genetic material to treat or prevent breast cancer.
Innovative cell therapy solutions for breast cancer, leveraging immune cells like CAR-T and NK cells to precisely target and eliminate cancer cells.
Targeted development of peptidomimetic drugs that mimic natural peptides, offering enhanced stability and effectiveness against breast cancer.
Advanced vaccine development services focused on creating therapeutic vaccines to stimulate the immune system to fight breast cancer.
Focused on developing drugs that target specific breast cancer markers to enhance treatment precision.
Supporting all phases of breast cancer research, from diagnostics to basic studies.
Customized cell lines are established through primary culture and genetic engineering. These validated models provide reliable in vitro systems for drug screening and mechanistic studies, ensuring human disease relevance.
Physiologically relevant 3D models (e.g., organoids and scaffold) replicate key tumor microenvironment features. These platforms enhance predictive accuracy for drug response and penetration studies, bridging 2D and in vivo models.
Comprehensive animal models, including PDX, CDX and GEMM, support in vivo efficacy evaluation. These systems enable translational research on tumor growth and therapy response in physiological contexts.
As a committed preclinical research service provider focused on cancer, Alfa Ctytology’s one-stop drug discovery services and a range of technology platforms will address the diverse needs of our clients, guaranteeing innovative and effective research results.
Learn MoreAlfa Cytology offers end-to-end preclinical development services for breast cancer therapies, covering drug discovery, in vitro validation, in vivo evaluation, and candidate optimization.
Learn MoreAlfa Cytology establishes syngeneic mouse models using the 4T1 breast cancer cell line to simulate tumor progression and immune responses, supporting efficacy studies for various therapeutic approaches.
Learn MoreProviding innovative antibody-drug conjugate (ADC) development services from target screening and antibody optimization to conjugation strategy evaluation, enabling precision therapy research for breast cancer.
Learn MoreUtilizing diverse oncolytic virus platforms, we conduct in vitro and in vivo efficacy assessments and mechanism studies to advance preclinical exploration of novel viral therapies for breast cancer.
Learn MoreDeveloping and optimizing nanoparticle-based photothermal therapy strategies to achieve targeted tumor ablation through precise localization and efficient thermal effects.
Learn More
